Hematopoietic Cell Transplantation for Aplastic Anemia and Other Bone Marrow Failure Syndromes — CPB 0627 | AETNA Coverage Update

Aetna modified CPB 0627 governing hematopoietic cell transplantation for aplastic anemia and bone marrow failure syndromes, effective December 12, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated this coverage policy under CPB 0627 Aetna system — covering allogeneic transplantation procedures billed under CPT 38230 and 38240, along with HLA typing codes 86813, 86817, and 86821. The policy draws a hard line between covered allogeneic transplants and non-covered autologous procedures under CPT 38232 and 38241. If your team bills for hematopoietic cell transplantation in any of the six covered conditions, this update sets the clinical thresholds your documentation must hit to support medical necessity.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Hematopoietic Cell Transplantation for Aplastic Anemia and Other Bone Marrow Failure Syndromes
Policy Code	CPB 0627
Change Type	Modified
Effective Date	December 12, 2025
Impact Level	High
Specialties Affected	Hematology/Oncology, Bone Marrow Transplant Programs, Hospital Billing, Revenue Cycle
Key Action	Audit documentation for all active transplant cases to confirm lab values meet CPB 0627 thresholds before billing CPT 38230 or 38240

---

Aetna Hematopoietic Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2025

The central question in Aetna's hematopoietic cell transplantation coverage policy is straightforward: does the member meet the transplanting institution's selection criteria? If yes, Aetna considers allogeneic hematopoietic cell transplantation medically necessary across five core conditions — severe aplastic anemia, Diamond-Blackfan anemia, Fanconi's anemia, paroxysmal nocturnal hemoglobinuria (PNH), and pure red cell aplasia.

The real issue comes when no institutional criteria exist. Aetna fills that gap with its own quantitative thresholds, and they're specific. For severe aplastic anemia, the member must meet at least three of four criteria:

For pure red cell aplasia, both criteria must be present — not just one. Bone marrow cellularity must be below 25%, and reticulocyte count must be below 1% or below 20 × 10⁹/L. Miss one of those, and you're looking at a medical necessity denial.

Diamond-Blackfan anemia coverage requires documented corticosteroid refractoriness. Fanconi's anemia requires severe bone marrow failure, myelodysplastic syndrome, or acute myelogenous leukemia — any one of the three qualifies. PNH requires ongoing transfusion requirements plus a suitable HLA-matched donor. Your HLA typing claims under CPT 86813, 86817, and 86821 feed directly into that last requirement.

Congenital dyserythropoietic anemia is also covered — but the bar is higher. The member must be transfusion-dependent and must have failed both interferon alfa and splenectomy. Document both treatment failures explicitly. If your notes only show one, expect a denial.

Aetna also covers repeat allogeneic stem cell transplantation when the original graft fails. Primary graft failure, failure to engraft, or rejection in any of the five core conditions all qualify. Prior authorization requirements for transplant cases of this complexity are essentially guaranteed — confirm your authorization is in place and specifies both the indication and the repeat transplant status before you submit.

---

Aetna Hematopoietic Cell Transplantation Exclusions and Non-Covered Indications

Autologous transplantation is flatly excluded. Aetna considers autologous hematopoietic cell transplantation experimental, investigational, or unproven for all five core conditions: severe aplastic anemia, Diamond-Blackfan anemia, Fanconi's anemia, paroxysmal nocturnal hemoglobinuria, and pure red cell aplasia.

The clinical reasoning is that effectiveness hasn't been established for autologous approaches in these indications. That's not likely to change based on this policy update. If your team bills CPT 38232 or 38241 for any of these conditions under an Aetna plan, expect a claim denial. This isn't an edge case — it's an explicit exclusion in the policy language.

Don't try to work around it with alternative coding. The non-covered status is tied to the indication, not just the procedure code. Document the indication clearly so you aren't accidentally submitting a covered code against a non-covered diagnosis combination.

---

Coverage Indications at a Glance

---

Aetna Hematopoietic Cell Transplantation Billing Guidelines and Action Items 2025

This update has high financial exposure. Transplant cases carry six-figure reimbursement potential — and equally large denial risk if your documentation doesn't match the policy thresholds exactly. Work through these steps before the effective date of December 12, 2025.

Copy Action Items

If your program handles high volumes across multiple transplant indications, have your compliance officer review your documentation templates against CPB 0627's specific thresholds before December 12, 2025. The precision Aetna requires here is not typical of most bone marrow transplant billing guidelines — it's worth a formal review.

---

CPT, HCPCS, and ICD-10 Codes for Hematopoietic Cell Transplantation Under CPB 0627

Covered CPT and HCPCS Codes (When Selection Criteria Are Met)

Not Covered / Experimental Codes

Code	Type	Description	Reason Copy
38232	CPT	Bone marrow harvesting for transplantation; autologous	Autologous transplantation considered experimental/investigational for all listed indications
38241	CPT	Hematopoietic progenitor cell (HPC); autologous transplantation	Autologous transplantation considered experimental/investigational for all listed indications

Other CPT Codes Related to CPB 0627

These codes are referenced in the policy but are not covered or excluded in isolation — they support clinical workup, preparation, and related procedures.

Bone Marrow and Stem Cell Services (CPT 38204–38215)

Splenectomy Codes

Blood Count Codes (CPT 85004–85049, 85055, 85060, 85097)

Compatibility Testing

Interferon Alfa Codes (HCPCS)

Code	Type	Description Copy
J9212	HCPCS	Injection, interferon alfacon-1, recombinant, 1 microgram
J9213	HCPCS	Injection, interferon, alfa-2a, recombinant, 3 million units
J9214	HCPCS	Injection, interferon, alfa-2b, recombinant, 1 million units

Note on ICD-10-CM Codes: The policy document does not list specific ICD-10-CM codes. Map your claims to the appropriate diagnosis codes for each condition (severe aplastic anemia, Fanconi's anemia, etc.) and confirm with your coding team that the diagnosis supports the specific indication pathway documented in the chart.

---